• Skip to main content
  • Skip to secondary menu
  • Skip to footer

Press Media Release

press release distribution

  • Submit a Press Release
  • Market Wire
  • Make a Contribution
  • About
    • Template for press/media release
    • How to structure your press release for maximum impact
    • Crafting effective headlines and leads to capture journalists’ attention
    • Understanding the dos and don’ts of writing press releases
    • Tips for writing clear, concise, and informative press releases
    • The importance of understanding your audience before writing a press release
    • Best practices for incorporating quotes and statistics in your press release
    • Writing effective boilerplates and about us sections for press releases
    • Identifying key media contacts and building relationships with journalists
    • Writing for different types of media, such as print, online, and social media
    • Measuring the success of your press release and tracking media coverage
  • Contact
    • GDPR

COVID-19: Sanofi to donate 100 million doses of hydroxychloroquine across 50 countries

April 10, 2020 By admin Leave a Comment

As of today, Sanofi has committed to donating 100 million doses of hydroxychloroquine to 50 countries around the world, and has begun to progressively deliver the medicine to authorities that have requested it.

Hydroxychloroquine donation
In this global health emergency, Sanofi stands ready to assist as many countries as possible, starting with countries where its medicine is registered for current approved indications as well as countries where there are no hydroxychloroquine suppliers or countries with underserved populations.

Since the beginning of the COVID-19 crisis, Sanofi has received a growing number of requests from local governments around the world. The company is regularly evaluating its increasing supply capacity and re-assessing how best to help those countries in the most ethical way. Sanofi’s priority is to ensure supply continuity for patients treated under the current approved indications of the medicine, notably including lupus and rheumatoid arthritis, while working hard to supply governments wishing to increase stocks in the hope that it may be an effective treatment of COVID-19.

Sanofi will continue to donate the medicine to governments and hospital institutions if ongoing clinical studies demonstrate its efficacy and safety in COVID-19 patients.

Production capacity ramp up
Sanofi has already doubled its incremental production capacity (on top of the usual production for current indications) across its eight hydroxychloroquine manufacturing sites worldwide and is on track to quadruple it by the summer.

Call for greater international cooperation
Sanofi is calling for coordination among the entire hydroxychloroquine chain worldwide to ensure the continued supply of the medicine if proven to be a well-tolerated and effective treatment in COVID-19 patients.

“The COVID-19 pandemic is an unprecedented health and economic crisis which is shaking some of the very fundamentals of international solidarity and cooperation among countries”, says Paul Hudson, Chief Executive Officer at Sanofi. “This virus does not care about the concept of borders, so we shouldn’t either. It is critical that international authorities, local governments, manufacturers, and all the other players involved in the hydroxychloroquine chain work together in a coordinated manner to ensure all patients who may benefit from this potential treatment can access it. If the trials prove positive, we hope our donation will play a critical role for patients.”

The company is already actively working with different stakeholders at local and international levels, and is ready to play its part in contributing to a more coordinated global initiative.

Ensure patient safety
At this point, the interpretations of the available preliminary data on hydroxychloroquine in the management of COVID-19 differ widely. In this context, patient safety must always be the guiding principle.

Hydroxychloroquine has several serious known side effects and should be used with caution. Not everyone can take this medicine.

To date, there is insufficient clinical evidence to draw any conclusion over the safety and efficacy of hydroxychloroquine in the management of COVID-19 patients. It is one of several medicines being investigated by the World Health Organization (WHO) in its international clinical trial seeking a treatment solution for COVID-19. Sanofi is supporting ongoing trials by providing the medicine to some participating investigator sites and other independent research centers.

While hydroxychloroquine is generating a lot of hope for patients around the world, it should be remembered that there are no results from ongoing studies, and the results may be positive or negative.

Sanofi’s efforts in the fight against COVID-19
Sanofi remains at the forefront of initiatives to fight the coronavirus, while also carrying on the daily business of making and delivering important medicines for patients. The company is also exploring alternative treatment options such as Kevzara® (sarilumab) for severe COVID-19 patients, and leveraging its expertise to develop a new vaccine. Both measures could have an immediate and a lasting impact. Dealing with a pandemic as daunting as COVID-19 requires collaboration to create as many paths forward as possible, and Sanofi is helping lead the way, playing its part.

Source: Sanofi

Filed Under: Press Release Tagged With: COVID-19

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Footer

Recent Posts

  • Explore the Future of Silicone Technology with Trelleborg at Silicone Expo
  • U.S. Conference of Mayors Continues to Stand with Ukraine
  • Junevity’s Pioneering RESET Platform Garners $10 Million Seed Investment to Transform Age-Related Disease Treatment
  • Festive Splendor: Christmas Market Magic in Vienna
  • The Art of the Photo Press Release
  • The Future of Press Release Distribution
  • Local vs. Global Press Release Distribution
  • Crafting the Perfect Distribution Schedule
  • Common Mistakes in Press Release Distribution
  • Press Releases: A Cost-Effective Marketing Tool

Media Partners

  • Press Club US
  • ZGM.org: Zeitgeist Generative Media
  • MSL.net: Media Sharing Lab
  • Policymaker.net
The Growing Divide Over Climate Change Policies
The Imminent Fall of Yahya Sinwar
Erdogan threatens to invade Israel
FOX News Media's Simulcast of CNN Presidential Debate Dominates Television with 13.4 Million Viewers
U.S. Response Inadequate as Houthi Attacks on Ships in the Red Sea Disrupt Global Maritime Shipping
The flood of goods to Russia via third countries is a global problem
TaiwanPlus Celebrates Three Years as a Leading International Media Organization, Nearing 200 Million Global Views
South Korea Reconsiders Arms Supply to Ukraine Amid Putin's Visit to North Korea
Broken Promises: Coke, Pepsi, and Others Still Operating in Russia Despite Pledges to Exit
Recalibrating Trade: A Stand for Economic Sovereignty
With Possible Strike Looming, Day Care Workers Deliver Solidarity Petition but Management Nowhere to Be Found
Exploring Market Dynamics: A Multifaceted Analysis Digest
The 16th Annual GoTopless Day Celebration, August 26, 2023, New York City
How I Built a Successful Side Hustle Creating 360-Degree Virtual Tours for Promoting Travel Destinations
Giving a Second Chance: The Power of Adopting Shelter Dogs
Exploring Subcultures: An In-depth Look into the Diverse Realms of Anime, Manga, and Shunga
Amplifying Voices: Generative Media's Role in Digital Activism and Social Justice
The Power of Pixels: A Call to Action Against Violence in Video Games
Beautiful.ai Adds Contextual AI Capabilities to DesignerBot, The Next Evolution of Generative AI
We stand with Israel
About
DN4B.com Event: Unleashing Digital Potential
The Heated Debate Over Immigration Policies in the U.S.
Scientific American Wins Seven Telly Awards
National Press Club Statement on Mexican Journalist Jesus Gutierrez Vergara Killed In Sonora
Charting the Erasmus: Mapping Blackthorne's Odyssey in Clavell's Shogun
Building a Successful Media Career
Genus AI Secures $6 Million in Seed Round Extension, Totaling $11 Million in Funding to Revolutionize E-commerce with Generative AI
Peru IX and PIT Colombia pioneer 400G in LATAM with Smartoptics
Canva to Acquire Generative AI Platform Leonardo.AI to Bring Leading Visual AI to Every Organization
Improving Treatment Access for Havana Syndrome: GAO Report Highlights Communication and Monitoring Gaps in DOD Response
Reducing Risks in Hypersonic Weapons Development: GAO Urges DOD to Adopt Leading Practices
AML/KYC Compliance AI-Focused Firm Axle Automation Raises $2.5M Led by Diagram Ventures
About
Erdogan threatens to invade Israel
Research from Fiber Broadband Association and RVA Reveals Gigabit Fiber Can Add $326B to U.S. GDP
Contact
The Majdal Shams tragedy is the result of the weak Biden and Harris administration
Venezuela's Democratic Opposition: Prospects and Challenges
The Druze community in Syria protests Hezbollah after the Majdal Shams massacre

Media Partners

  • Media Presser
  • 3V.org: PR/Media Agency
  • Publishing House
  • Media Instances
Posters.org Announces Workshop on Designing Impactful Conference Posters
MarketAnalysis.com Unveils Comprehensive Report on AI in DevOps
MarketAnalysis.com Announces Groundbreaking Report on the Potential of Lithium–Sulfur Batteries
Iran proposes amendments to a draft resolution on dark shipping at the upcoming meeting of the International Maritime Organization (IMO)
San Francisco Thought Leader Predicts That Government Turmoil and Disruption is Likely to Continue in 2024
Woolpert Hires Cloud Alliance Manager Zack Schreiber to Support Google Cloud Relationship
bluShift is a GO for Full Flight-Duration Engine Test
TravelMktg.com Highlights the Environmental Impact of the Cruise Industry
MarketAnalysis.com Releases Groundbreaking Market Research Report on Custom Photography Apps
Phenomenon of Westophobia: Unveiling Diverse Perspectives on Cultural Aversion
Hustle Your Story
Empowering Small Businesses: How MktgDev.com Transforms Marketing Strategies
Case Study in Travel Marketing: Revitalizing a Family-Run Hotel in Bergerac, France
Cybersecurity Digest
Analyze, Analyze, Analyze
bluShift Successfully Completed a Full Flight-Duration Engine Test Last Night at Brunswick Landing
Andy Murray: A Legacy of Tenacity and Triumph in Tennis
DefenseMarket.com Embraces Blockchain Technology for Enhanced Security and Transparency
Keir Starmer's Labour Party Achieves Historic Victory in UK General Election
Rishi Sunak's Campaign: A Perfect Storm of PR Failures
My Sicilian Adventures: Capturing Moments with the Canon R50
PublishingHouse.org Extends Heartfelt Gratitude to Media Partners for Their Unwavering Support
The Paris memorial for the 1972 Olympic massacre will be held in secret due to concerns about potential violence
Gender disparities across various aspects of life in Africa
Xi Jinping and the CCP Are Driving China's Economy into the Ground
Scotland's Former First Minister Humza Yousaf Faces Probe Over Unwittingly Channeling UK Government Funds to Hamas
Celebrating Liberty: The Vibrant Spirit of Bastille Day
Google is set to acquire the Israeli cybersecurity startup Wiz for $23 billion
Contact
The renowned billionaire investor and hedge fund manager Bill Ackman Publicly Endorses Trump
The Good Soldier Švejk: A Scene from the Satirical Novel
Case Study: Navigating Change: Transforming “Brands To Shop” into a Sustainable Fast Fashion Leader
5 Tips for Writing a Good Blog Post
Voyage Beyond Realms: Deciphering the Enigmatic Tapestry of ‘Echoes from Eternity’
TCL Enters Mobile Projector Market with the Launch of Projector A1
It was hot 600 years ago and they did not talk about climate change
If you want to support IsraelNews.org, click the link below
Movie Review: “The Red Circle” (1970)
4C Strategies and BISim Sign MoU to Advance Defense Training Interoperability
The Outlaw’s Last Ride: A Tribute to Spaghetti Westerns

Copyright © 2022 PressMediaRelease.com

Sponsored by Exclusive Domains